# Après-demain

Après-demain is a Single Family Office based in Lausanne, Switzerland.

## Overview

- **Organization type:** Single Family Office
- **Headquarters:** Lausanne, Switzerland
- **Region:** Europe
- **Address:** Chemin Messidor 5-7, 1006 Lausanne, Switzerland
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** apres-demain.com
- **LinkedIn:** https://www.linkedin.com/company/apr%C3%A8s-demain-sa

## Regulatory record

- **Reports private funds:** No

## About

Après-demain formalized in 2020 as the single-family office for Switzerland's Mauvernay family, whose wealth originates from Debiopharm — the privately held pharmaceutical company Dr. Rolland-Yves Mauvernay launched in 1979 and that his son Thierry joined in 2001. The firm is structured as the parent for a group now operating across four poles: the original life-science division, a responsible-capital-management arm built in the early 2000s, a philanthropic vehicle launched in 2010, and an impact-oriented division added in 2020 to target climate and social-precarity themes. The investment team allocates across private equity (buyout and growth), private debt (including mezzanine), real estate, secondaries, and fund commitments. Direct co-investment activity is visible in deal consortiums: the firm has backed cybersecurity training platform OffSec alongside Leeds Equity Partners, AI chip developer Tenstorrent with Georgian, and healthcare software company Hoppen alongside Extens and Geneo Capital Entrepreneur. The office also co-founded the Power Sustainable Energy Infrastructure Partnership with Desjardins Group, Great-West Lifeco, and National Bank of Canada, confirming an infrastructure allocation. Geographic exposure spans North America, Europe, Asia, and Oceania. The office operates from a single headquarters in Lausanne. Named deal-side professionals include Private Equity Director Sébastien Beth and Head of Private Debt Jean-Philippe Carvaillo. The team runs parallel tracks for direct investments and fund/co-investment selection, with Joanna Bildstein-Zimmer managing the fund-of-funds sleeve. Thierry Mauvernay simultaneously chairs Romande Energie Holding SA, adding an active-operating-company dimension to the governance model. In December 2024, the firm's LinkedIn listed ten deal professionals covering direct investments, funds, co-investments, and the GeneRActions Planet impact mandate. The structural differentiator is the integration of a revenue-generating life-science operating company under the same family holding. Debiopharm continues to develop oncology and infectious-disease therapies, and its cash flows — combined with an explicit asset-diversification division that predates the family-office entity — give Après-demain a self-funded, non-fundraising posture that can hold assets indefinitely without LP pressure. The parallel philanthropic foundation, Fondation Philanthropique Next, provides a separate channel for mission-related capital.

## Sectors

- Healthcare Services
- Energy Transition & Renewables
- ClimateTech
- EdTech
- AgriTech & FoodTech
- PropTech
- Circular Economy
- Data Analytics
- Industrial Tech
- Digital Health
- Mobility & Transportation
- AI/ML
- Biotech
- Cybersecurity
- Semiconductors
- Space Tech

## People

- Thierry Mauvernay — Chairman and CEO
- Sébastien Beth — Private Equity Director
- Jean-Philippe Carvaillo — Private Equity Associate Director, Head of Private Debt, Direct Investments
- Joanna Bildstein-Zimmer — Private Equity Manager, Funds & Co-Investments
- Benoit Junique — Private Equity Manager, Direct Investments
- Melvin Da Costa — Private Equity Associate, GeneRActions Planet
- Julien Leclerc — Private Equity Analyst, Direct Investments
- Adrien Lehmann — Private Equity Analyst, Direct Investments
- Eddy Chembah — Private Equity Analyst, Funds & Co-Investments
- Maximilien Portal — Private Equity Analyst, Funds & Co-Investments

## Questions

### Who runs investment decisions at Après-demain?

Thierry Mauvernay serves as Chairman and CEO, supported by a dedicated private-equity team. Sébastien Beth holds the Private Equity Director title, while Jean-Philippe Carvaillo leads private debt as Associate Director. The firm maintains separate coverage for direct investments, fund commitments, and co-investments under Joanna Bildstein-Zimmer.

### How does Après-demain source proprietary deal flow?

The firm co-invests alongside established GPs and strategic partners, including Leeds Equity Partners (OffSec), Georgian (Tenstorrent), and Extens/Geneo Capital Entrepreneur (Hoppen). Its affiliation with Debiopharm also creates origination channels in healthcare, and its role as a founding partner in the Power Sustainable Energy Infrastructure Partnership provides infrastructure deal access.

### Is Après-demain a pure family office or does it operate a venture arm?

Après-demain functions as the parent entity for the Mauvernay family's four divisions: life sciences (Debiopharm), traditional asset diversification, philanthropy, and impact investing. The investment team allocates across the full private-markets stack — buyout, growth, debt, secondaries, and fund-of-funds — rather than operating as a standalone venture firm.

### Does Après-demain participate in fund commitments or only direct deals?

Both. The team structure includes a Funds & Co-Investments unit led by Joanna Bildstein-Zimmer alongside a Direct Investments unit. The firm's stated strategy covers co-investments, fund of funds, and direct private equity.

### What investment stages does Après-demain typically target?

The firm's confirmed stages are buyout and growth. Its direct-deal examples, such as Tenstorrent and Hoppen, indicate growth-stage activity, while the presence of private debt and secondaries adds late-stage and structured exposure.

### What is Après-demain's relationship to Debiopharm?

Après-demain SA is the parent company of the group that includes Debiopharm as its life-science division. Thierry Mauvernay leads both the family office and the pharmaceutical operations, allowing the group to reinvest pharmaceutical proceeds directly into the diversified asset portfolio.

## Related profiles

- [Wah Hin & Co](https://altss.com/profile/wah-hin-and-co-pte-ltd-wh)
- [Wilson & Co Investments](https://altss.com/profile/wilson-and-co-investments)

---

Last updated: 2026-08-10T15:54:10.904Z

Canonical page: https://altss.com/profile/apres-demain-sa

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology